Sai Life Sciences

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, announced that it has signed a non-exclusive license agreement with…

For years, China+1 has been the big story in India's CDMO opportunity. Now, it is no longer enough. The shift away from China is…

Sai Life Sciences, an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced the…

The expansion increases total reactor capacity to ~700 KL, supporting large-scale API and intermediate manufacturing for regulated…

Sai Life Sciences adopts DHL’s GoGreen Plus service to reduce greenhouse gas emissions by 90 per cent using sustainable aviation…

The new facility expands peptide synthesis and discovery capabilities for pharma and biotech companies

It will accelerate drug discovery and boost clinical research and process development labs

Initiates first phase of recruitment for 100 scientists in API process development and scale-up

It has over 2000 employees across its facilities in India, UK and US

The company, through an initiative named Sai Nxt, is investing over $150 million (> Rs 1000 crores) to expand and upgrade its…